U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968910) titled 'CBD-based Therapy to Attenuate Non-bacterial Prostatitis Symptoms' on April 26.
Brief Summary: Efficacy and safety of the medical device rectal CANNEFF(R) SUP suppositories containing two active ingredients cannabidiol (CBD) and hyaluronic acid (HA) in alleviating non-bacterial prostatitis symptoms and improving quality of life in men will be evaluated.
Study Start Date: Dec. 01, 2022
Study Type: INTERVENTIONAL
Condition:
Prostatitis
Intervention:
DEVICE: CANNEFF(R) SUP rectal suppositories
CANNEFF(R) SUP suppositories with cannabidiol (CBD = 100 mg) and hyaluronic acid (HA = 6.6 mg) as active ingredients
Recruitment Status: ...